z-logo
open-access-imgOpen Access
Romosozumab, clinical trials, and real-world care of patients with osteoporosis
Author(s) -
E. Michael Lewiecki
Publication year - 2020
Publication title -
annals of translational medicine
Language(s) - English
Resource type - Journals
eISSN - 2305-5847
pISSN - 2305-5839
DOI - 10.21037/atm.2020.03.196
Subject(s) - medicine , osteoporosis , clinical trial
New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA Correspondence to: E. Michael Lewiecki, MD. New Mexico Clinical Research & Osteoporosis Center, 300 Oak St. NE, Albuquerque, NM 87106, USA. Email mlewiecki@gmail.com. Provenance: This is an invited article commissioned by the Academic Editor Dr. Yusheng Li (Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, China). Comment on: McClung MR, Brown JP, Diez-Perez A, et al. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study. J Bone Miner Res 2018;33:1397-406.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom